Evidence map›Paper›PMID 33356304›Full record

ArticleJournal of proteome research2021

Proteomic Data Analysis for Differential Profiling of the Autoimmune Diseases SLE, RA, SS, and ANCA-Associated Vasculitis.

Mattias Ohlsson, Thomas Hellmark, Anders A Bengtsson, Elke Theander, Carl Turesson, Cecilia Klint, Christer Wingren, Anna Isinger Ekstrand

Abstract read
In one paragraph

Article in Journal of proteome research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mattias OhlssonComputational Biology & Biological Physics, Department of Astronomy and Theoretical Physics, Lund University, Sölvegatan 14A, Lund SE-221 00, Sweden.
Thomas HellmarkDepartment of Clinical Sciences Lund, Nephrology, Skåne University Hospital Lund, Lund University, Lund SE-221 85, Sweden.
Anders A BengtssonRheumatology, Department of Clinical Sciences, Lund, Lund University, Lund SE-221 00, Sweden.
Elke TheanderRheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö SE-221 00, Sweden.
Carl TuressonDepartment of Rheumatology, Skåne University Hospital, Lund and Malmö SE-214 28, Sweden.
Cecilia KlintImmunovia AB, Lund 223 81, Sweden.
Christer WingrenDepartment of Immunotechnology, Lund University, Medicon Village, Scheelevägen 2, Lund SE-223 81, Sweden.
Anna Isinger EkstrandDepartment of Immunotechnology, Lund University, Medicon Village, Scheelevägen 2, Lund SE-223 81, Sweden.ORCID 0000-0002-6651-7091

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early and correct diagnosis of inflammatory rheumatic diseases (IRD) poses a clinical challenge due to the multifaceted nature of symptoms, which also may change over time. The aim of this study was to perform protein expression profiling of four systemic IRDs, systemic lupus erythematosus (SLE), ANCA-associated systemic vasculitis (SV), rheumatoid arthritis (RA), and Sjögren's syndrome (SS), and healthy controls to identify candidate biomarker signatures for differential classification. A total of 316 serum samples collected from patients with SLE, RA, SS, or SV and from healthy controls were analyzed using 394-plex recombinant antibody microarrays. Differential protein expression profiling was examined using Wilcoxon signed rank test, and condensed biomarker panels were identified using advanced bioinformatics and state-of-the art classification algorithms to pinpoint signatures reflecting each disease (raw data set available at https://figshare.com/s/3bd3848a28ef6e7ae9a9.). In this study, we were able to classify the included individual IRDs with high accuracy, as demonstrated by the ROC area under the curve (ROC AUC) values ranging between 0.96 and 0.80. In addition, the groups of IRDs could be separated from healthy controls at an ROC AUC value of 0.94. Disease-specific candidate biomarker signatures and general autoimmune signature were identified, including several deregulated analytes. This study supports the rationale of using multiplexed affinity-based technologies to reflect the biological complexity of autoimmune diseases. A multiplexed approach for decoding multifactorial complex diseases, such as autoimmune diseases, will play a significant role for future diagnostic purposes, essential to prevent severe organ- and tissue-related damage.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisArthritis, RheumatoidAutoimmune DiseasesLupus Erythematosus, SystemicSjogren's SyndromeData AnalysisHumansProteomicsantibody microarrayautoimmune diseasesproteomicswhole blood

Identifiers

PMID33356304
PMCPMC7872503

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.